Litigation Details for Sanofi-Aventis U.S. LLC v. Sandoz Inc. (D. Del. 2020)
✉ Email this page to a colleague
Sanofi-Aventis U.S. LLC v. Sandoz Inc. (D. Del. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-06-12 |
| Court | District Court, D. Delaware | Date Terminated | 2023-07-05 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,583,110; 7,241,907; 8,927,592 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sanofi-Aventis U.S. LLC v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Sanofi-Aventis U.S. LLC v. Sandoz Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-09-09 | 107 | *989 This appeal involves U.S. Patent No. 8,927,592 (“the ’592 patent”), which is assigned to Sanofi …claims 1–5 and 7–30 of U.S. Patent No. 8,927,592 (Ex. 1001, “the ’592 patent”). Paper 3 (“Petition” …1365 IPR2016-00712 Patent 8,927,592 B2 Patent Owner filed a Reply to Petitioner…1366 IPR2016-00712 Patent 8,927,592 B2 17, 2017, Patent Owner appealed to the Court of…claims 21 and 30 of U.S. Patent No. 8,927,592 (“the ’592 patent”) under 35 U.S.C. § | External link to document | |
| 2020-11-03 | 143 | Redacted Document | 11/03/20 Page 8 of 27 PageID #: 2085 8,927,592 Methods of treating a …Orange Book-listed patents, including the ’170 patent and ’907 patent. Ex. 15, Patent Cert. Pursuant to… Count I: Infringement of U.S. Patent No. 10,583,110 (“’110 patent”) under 35 U.S.C. § 271…110 patent under 35 U.S.C. § 271(b); • Count III: Infringement of U.S. Patent No. …of Sanofi as to the ’170 patent, but vacated the judgment on the ’592 patent for the disclaimed claims | External link to document |
| 2020-12-02 | 178 | Letter | case involves two patents—U.S. Patent Nos. 10,583,110 and 10,716,777 (the “Patents-in-Suit”)—that cover…involved different patents, one of which (U.S. Patent No. 8,927,592 (the “’592 Patent”)) Case 1:20-cv-00804…applications leading to the Patents-in-Suit. Although the claims of the three patents are different, the specifications…transcripts concerning the subject matter of U.S. Patent No. 8,927,592 from the Consolidated Prior New Jersey…6) regarding several Topics concerning the ’592 Patent, the examples disclosed therein, the TROPIC study | External link to document |
| 2021-01-05 | 209 | Memorandum Opinion | U.S. Patent No. 10,583,110 (“the ‘110 Patent”) and U.S. Patent No. 10,716,777 (“the ‘777 Patent”). The…OPINION providing claim construction for U.S. Patent Nos. 10,583,110 and 10,716,777. Within five days the parties… defined in the ‘110 and ‘777 Patents. ‘110 Patent 11:20-22; ‘777 Patent 11:19-20. This understanding …administration of said cabazitaxel.” ‘110 Patent 18:8-18. Claim 1 of the ‘777 Patent discloses a method using a “dose…cabazitaxel.” ‘777 Patent 18: 54- 61. 1 1 Why the ‘777 Patent, which is a continuation | External link to document |
| 2021-01-11 | 215 | Order | following te1ms in U.S. Patent Nos. 10,583,110 ("the '110 patent") and 10,716,777 ("…;777 patent") are constmed as set f01ih below: Term Patent Claims…resistant metastatic prostate cancer '110 patent: claim 1 castration resistant metastatic …after or after treatment with '777 patent: claim 1 treatment with docetaxel 1 docetaxel…the a method of increasing '110 patent: claim 1 intentional pmpose of increasing | External link to document |
| 2021-08-30 | 248 | Exhibits A-D | States Patent ( 10 ) Patent No.: US 10,583,110 B2 … US 10,583,110 B2 … US 10,583,110 B2 … US 10,583,110 B2 … US 10,583,110 B2 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
